Acorda Therapeutics Inc.'s stock plunged 21.4 percent after FDA drug reviewers raised concerns in briefing documents about the efficacy of Amaya (fampridine sustained-release) in improving the walking ability in patients with multiple sclerosis. (BioWorld Today) Read More
